State

US Virgin Islands product recalls

73,824 recalls have nationwide distribution and so reach US Virgin Islands. 178 additional recalls listed US Virgin Islands specifically in their distribution scope.

What the numbers show

Total: 178
Critical: 12
Severe: 39
Most recent: 2026-10-21

Of the 178 recalls naming US Virgin Islands we have scored against our rubric, 12 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 39 (22%) are Severe.

Which agencies issued them

These figures cover only the 178 recalls whose distribution notice names US Virgin Islands specifically. The 73,824 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

54401–54425 of 74002

SevereFDA (Drugs)·D-730-2015·2015-04-29
Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-910-2015·2015-04-29
Tacrolimus Monohydrate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Tacrolimus Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tacrolimus Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-697-2015·2015-04-29
Attix Pharmaceuticals Recalls Gatifloxacin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Gatifloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Gatifloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-872-2015·2015-04-29
Attix Pharmaceuticals Recalls Pyridostigmine Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pyridostigmine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Pyridostigmine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-815-2015·2015-04-29
Attix Pharmaceuticals Recalls Neostigmine Methylsulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Neostigmine Methylsulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Neostigmine Methylsulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-712-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydrochlorothiazide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydrochlorothiazide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydrochlorothiazide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-788-2015·2015-04-29
Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Methscopolamine Bromide Combo active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-638-2015·2015-04-29
Attix Pharmaceuticals Recalls Dopamine HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dopamine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Dopamine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-725-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyoscine Butylbromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hyoscine Butylbromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Hyoscine Butylbromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-554-2015·2015-04-29
Cabergoline API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Cabergoline active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Cabergoline active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-763-2015·2015-04-29
Lincomycin HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Lincomycin HCl Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Lincomycin HCl Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-530-2015·2015-04-29
Avanafil API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling all lots of Avanafil active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Avanafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-575-2015·2015-04-29
Attix Pharmaceuticals Recalls Chloramphenicol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Chloramphenicol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Chloramphenicol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-517-2015·2015-04-29
Attix Pharmaceuticals Recalls Amlodipine Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Amlodipine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Amlodipine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-698-2015·2015-04-29
Gefitinib API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Gefitinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Gefitinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-572-2015·2015-04-29
Attix Pharmaceuticals Recalls Cephalexin Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cephalexin Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Cephalexin Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-837-2015·2015-04-29
Attix Pharmaceuticals Recalls Pergolide Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pergolide Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Pergolide Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-793-2015·2015-04-29
Attix Pharmaceuticals Recalls Metronidazole Base Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Metronidazole Base active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Metronidazole Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-931-2015·2015-04-29
Attix Pharmaceuticals Recalls Tizanidine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tizanidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Tizanidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-594-2015·2015-04-29
Attix Pharmaceuticals Recalls Clomiphene Citrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Clomiphene Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Clomiphene Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-713-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydrocortisone Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling hydrocortisone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydrocortisone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-823-2015·2015-04-29
Attix Pharmaceuticals Recalls Omeprazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Omeprazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Omeprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-658-2015·2015-04-29
Attix Pharmaceuticals Recalls Estrone API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Estrone active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.
Product
Estrone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-508-2015·2015-04-29
Alpha Chymotrypsin Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Alpha Chymotrypsin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Alpha Chymotrypsin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-864-2015·2015-04-29
Attix Pharmaceuticals Recalls Procaine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Procaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.
Product
Procaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide